Advertisement

DNA Repair and the Carrier Ligand Specificity of Platinum Resistance

  • Stephen G. Chaney
  • Edward L. Mamenta

Abstract

The major mechanisms of platinum resistance at the DNA level appear to be enhanced DNA repair and increased tolerance of Pt-DNA adducts. It is clear that enhanced repair activity, as measured by removal of Pt-DNA adducts from genomic DNA, is observed in a great many platinum-resistant cell lines (1–3). This enhanced removal of Pt-DNA adducts most likely represents an increase in nucleotide excision repair capacity (4), since that is the only repair process which has been shown to remove Pt-DNA adducts. Furthermore, those cell lines with defects in nucleotide excision repair show enhanced sensitivity to platinum complexes (5,6). Recent research has defined the enzymes needed for nucleotide excision repair (7). However, it is not yet clear which of these enzymes are limiting for nucleotide excision repair in vivo and are, therefore, increased in amount and/or activity in cisplatin-resistant cell lines. For example, Dabholkar et al. (8,9) have reported increased expression of ERCC1 and XPAC in tissue from patients who were resistant to cisplatin chemotherapy. However, both Katz et al. (10) and Sheibani and Eastman (11) have found no increased expression of ERCC1 in cisplatin-resistant cell lines. Similarly, we have found no increased expression or cisplatin-inducibility of XPAC in cisplatin-resistant cell lines (Vaisman et al., manuscript in preparation).

Keywords

Nucleotide Excision Repair Platinum Complex DHFR Gene Human Ovarian Carcinoma Cell Line Nucleotide Excision Repair System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Andrews, P.A., and Howell, S.B., Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2: 35–43, 1990.PubMedGoogle Scholar
  2. 2.
    Johnson, S.W., Ozols, R.F., and Hamilton, T.C. Mechanisms of drug resistance in ovarian cancer. Cancer, 71: 644–649,1993.CrossRefPubMedGoogle Scholar
  3. 3.
    Calsou, P. and Salles, B. Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin. Cancer Chemother. Pharmacol., 32: 85–89, 1993.CrossRefPubMedGoogle Scholar
  4. 4.
    Sancar, A., and Tang, M.S. Nucleotide Excision Repair. Photochem. Photobiol., 57: 905–921, 1993.CrossRefPubMedGoogle Scholar
  5. 5.
    Sheibani, N., Jennerwein, M.M., and Eastman, A. DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II):host cell reactivation of damaged plasmid DNA. Biochemistry, 28: 3120–3124, 1989.CrossRefPubMedGoogle Scholar
  6. 6.
    Demarcq, C., Bunch, R.T., Creswell, D., and Eastman, A. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ., 5: 983–993, 1994.PubMedGoogle Scholar
  7. 7.
    Sancar, A. Mechanisms of DNA excision repair. Science, 266: 1954–1956, 1994.CrossRefPubMedGoogle Scholar
  8. 8.
    Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V.A., Egwuagu, C., and Reed, E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J. Nat. Cancer Inst., 84: 1512–1517, 1992.CrossRefPubMedGoogle Scholar
  9. 9.
    Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J.J., and Reed, E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest., 94: 703–708, 1994.CrossRefPubMedGoogle Scholar
  10. 10.
    Kratz, E.J., Andrews, P.A., and Howell, S.B. The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells. Cancer Commun., 2: 159–164, 1990.Google Scholar
  11. 11.
    Sheibani, N., and Eastman, A. Analysis of various mRNAs potentially involved in cisplatin resistance of murine leukemia L1210 cells. Cancer Lett., 52: 179–185, 1990.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhen, W.P., Link, C.J., O’Connor, P.M., Reed, E., Parker, R., Howell, S.B., and Bohr, V.A. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol. Cell Biol, 12: 3689–3698, 1992.PubMedGoogle Scholar
  13. 13.
    May, A., Nairn, R.S., Okumoto, D.S., Wassermann, K., Stevnsner, T., Jones, J.C., and Bohr, V.A. Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin. J. Biol. Chem., 268: 1650–1657, 1993.PubMedGoogle Scholar
  14. 14.
    Larminat, F., Zhen, W.P., and Bohr, V.A. Gene-specific DNA repair of interstrand cross-links induced by chemotherapeutic agents can be preferential. J. Biol. Chem., 268: 2649–2654, 1993.PubMedGoogle Scholar
  15. 15.
    Larminat, F., and Bohr, V.A. Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage. Nucleic. Acids. Res., 22: 3005–3010, 1994.CrossRefPubMedGoogle Scholar
  16. 16.
    Johnson, S.W., Perez, R.P., Godwin, A.K., Yeung, AT., Handel, L.M., Ozols, R.F., and Hamilton, T.C. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol., 47: 689–697, 1994.CrossRefPubMedGoogle Scholar
  17. 17.
    Johnson, S.W., Swiggard, P.A., Handel, L.M., Brennan, J.M., Godwin, A.K., Ozols, R.F., and Hamilton, T.C. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and-resistant human ovarian cancer cells. Cancer Res., 54: 5911–5916, 1994.PubMedGoogle Scholar
  18. 18.
    Gibbons, G.R., Page, J.D., Mauldin, S.K., Husain, I., and Chaney, S.G. Role of carrier ligand in platinum resistance in L1210 cells. Cancer Res., 50: 6497–6501, 1990.PubMedGoogle Scholar
  19. 19.
    Schmidt, W., and Chaney, S.G. Role of Carrier Ligand in Platinum Resistance of Human Carcinoma Cell Lines. Cancer Res., 53: 799–805, 1993.PubMedGoogle Scholar
  20. 20.
    Rawlings, C.J., and Roberts, J.J. Walker rat carcinoma cells are exceptionally sensitive to cis-diamminedichloroplatinum(II) (cisplatin) and other difunctional agents but not defective in the removal of platinum-DNA adducts. Mutat. Res., 166: 157–168, 1986.CrossRefPubMedGoogle Scholar
  21. 21.
    Shellard, S.A., Hosking, L.K., and Hill, B.T. Anomolous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro. Cancer Res., 51: 4557–4564, 1991.PubMedGoogle Scholar
  22. 22.
    Hill, B.T., Shellard, S.A., Hosking, L.K., Fichtinger-Schepman, A.MJ., and Bedford, P. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diamminedichloroplatinum(II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation. Int. J. Radiat. Oncol. Biol. Phys., 19: 75–83, 1990.CrossRefPubMedGoogle Scholar
  23. 23.
    Shellard, S.A., Fichtinger-Schepman, A.M.J., Lazo, J.S., and Hill, B.T. Evidence of differential cisplatin DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anti-Cancer. Drug, 4: 491–500, 1993.CrossRefGoogle Scholar
  24. 24.
    Jekunen, A.P., Horn, D.K., Alcarez, J.E., Eastman, A., and Howell, S.B. Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and-resistant human ovarian carcinoma cells. Cancer Res., 54: 2680–2687, 1994.PubMedGoogle Scholar
  25. 25.
    Mamenta, E.L., Poma, E.E., Kaufmann, W.K., Delmastro, D.A., Grady, H.L., and Chaney, S.G. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res., 54: 3500–3505, 1994.PubMedGoogle Scholar
  26. 26.
    Eastman, A., and Schulte, N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry, 27: 4730–4734, 1988.CrossRefPubMedGoogle Scholar
  27. 27.
    Wilkoff, LJ., Dulmadge, E.A., Trader, M.W., Harrison, S.D. Jr., and Griswold, D.P. Evaluation of trans-tetrachloro-1,2-diaminocyclohexane platinum (IV) in murine leukemia L1210 resistant and sensitive to cis-diamminedichloroplatinum (II). Cancer Chemother. Pharmacol., 20: 96–100, 1987.CrossRefPubMedGoogle Scholar
  28. 28.
    Behrens, B.C., Hamilton, T.C., Masuda, H., Grotzinger, K.R., Whang-Peng, J., Louie, K.G., Knutsen, T., McKoy, W.M., Young, R.C., and Ozols, R.F. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res., 47: 414–418, 1987.PubMedGoogle Scholar
  29. 29.
    Teicher, B.A., Holden, S.A., Herman, T.S., Stomayor, E.A., Khandekar, V., Rosbe, K.W., Brann, T.W., Korbut, T.T., and Frei, E. III Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int. J. Cancer, 47: 252–260, 1991.CrossRefPubMedGoogle Scholar
  30. 30.
    Perez, R.P., O’Dwyer, P.J., Handel, L.M., Ozols, R.F., and Hamilton, T.C. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines. Int. J. Cancer, 48: 265–269, 1991.CrossRefPubMedGoogle Scholar
  31. 31.
    Hills, C.A., Kelland, L.R., Abel, G., Riracky, J., Wilson, A.P., and Harrap, K.R. Biological properties of ten human ovarian cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer, 59: 527–534, 1989.CrossRefPubMedGoogle Scholar
  32. 32.
    Page, J.D., Husain, I., Sancar, A., and Chaney, S.G. Effect of the diammocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry, 29: 1016–1024, 1990.CrossRefPubMedGoogle Scholar
  33. 33.
    Kohn, K.W., and Grimek-Ewig, R.A. Alkaline elution analysis, a new approach to the study of DNA single-strand interuptions in cells. Cancer Res., 33: 1849–1853, 1973.PubMedGoogle Scholar
  34. 34.
    Micetich, K., Zwelling, L.A., and Kohn, K.W. Quenching of DNA:platinum(II) monoadducts as a possible mechanism of resistance to cis-diamminedichloroplatinum(II) in L1210 cells. Cancer Res., 43: 3609–3613, 1983.PubMedGoogle Scholar
  35. 35.
    Fram, R.J., Woda, B.A., Wilson, J.M., and Robichaud, N. Characterization of acquired resistance to cis-diamminedichloroplatinum(II) in BE human colon carcinoma cells. Cancer Res., 50: 72–77, 1990.Google Scholar
  36. 36.
    Hospers, G.A.P., Mulder, N.H., de Jong, B., de Ley, L., Uges, D.R.A., Fichtinger-Schepman, A.M.J., Scheper, R.J., and de Vries, E.G.E. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res., 48: 6803–6807, 1988.PubMedGoogle Scholar
  37. 37.
    Richon, V.M., Schulte, N., and Eastman, A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res., 47: 2056–2061, 1987.PubMedGoogle Scholar
  38. 38.
    Strandberg, M.C., Bresnick, E., and Eastman, A. The significance of DNA cross linking to cis-diamminedichloroplatinum(II)-induced cytotoxicity in sensitive and resistant lines of murine leukemia L1210 cells. Chem.-Biol. Interact., 39: 169–180, 1982.CrossRefPubMedGoogle Scholar
  39. 39.
    Strandberg, M.C., Bresnick, E., and Eastman, A. DNA crosslinking induced by 1, 2-diaminocyclohexanedichloroplatinum(II) in murine leukemia L1210 cells and comparison with other platinum analogs. Biochim. Biophys. Acta, 698: 128–133, 1982.CrossRefPubMedGoogle Scholar
  40. 40.
    Kaufmann, W.K. Pathways of human cell post-replication repair. Carcinogenesis, 10: 1–11, 1989.CrossRefPubMedGoogle Scholar
  41. 41.
    Hoffmann, J.-S., Johnson, N.P., and Villani, G. Conversion of monofunctional DNA adducts of cis-diamminedichloroplatinum(II) to bifunctional lesions. J. Biol. Chem., 264: 15130–15135, 1989.PubMedGoogle Scholar
  42. 42.
    Comess, K.M., Burstyn, J.N., Essigmann, J.M., and Lippard, S.J. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. Biochemistry, 31: 3975–3990, 1992.CrossRefPubMedGoogle Scholar
  43. 43.
    Gibbons, G.R., Kaufmann, W.K., and Chaney, S.G. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. Carcinogenesis, 12: 2253–2257, 1991.CrossRefPubMedGoogle Scholar
  44. 44.
    Jennerwein, M.M., Eastman, A., and Khokhar, A.R. Characterization of adducts produced in DNA by isomeric l, 2-diaminocyclohexaneplatinum(II) complexes. Chem.-Biol. Interact., 70: 39–49, 1989.CrossRefPubMedGoogle Scholar
  45. 45.
    Fichtinger-chepman, A.M.J., Vendrik, C.P.J., van Dijk-Knijnenburg, W.C.M., De Jong, W.H., van der Minnen, A.C.E., Claessen, A.M.E., van der Velde-Visser, S.D., de Groot, G., Wubs, K.L., Steerenberg, P.A., Schornagel, J.H., and Berends, F. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats innoculated with cisplatin-sensitive or resistant immunoglobulin M immunocytoma. Cancer Res., 49: 2862–2867, 1989.Google Scholar
  46. 46.
    Salles, B., Butour, J.L., Lesca, C., and Macquet, J.P. cis-Pt(NH3)2Cl2 and trans-Pt(NH3)2Cl2 inhibit DNA synthesis in cultured L1210 leukemia cells. Biochem. Biophys, Res. Commun., 112: 555–563, 1983.CrossRefGoogle Scholar
  47. 47.
    Sorenson, C.M. and Eastman, A. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cel 1 cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res., 48: 6703–6707, 1988.PubMedGoogle Scholar
  48. 48.
    Just, G., and Holler, E. Platinum incorporation and differential effects of cis-and trans-diamminedichloroplatinum(II) on the growth of mouse leukemia P388/D1. Cancer Res., 49: 7072–7077, 1989.PubMedGoogle Scholar
  49. 49.
    Boyer, J.C., Kaufmann, W.K., Brylawski, B.P., and Cordeiro-Stone, M. Defective post-replication repair in Xeroderma pigmentosum variant fibroblasts. Cancer Res., 50: 2593–2598, 1990.PubMedGoogle Scholar
  50. 50.
    Zinkewich-eotti, K., and Andrews, P.A. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine-123 resistance. Cancer Res., 52: 1902–1906, 1992.Google Scholar
  51. 51.
    Wassermann, K., Kohn, K.W., and Bohr, V.A. Heterogeneity of nitrogen-mustard-induced DNA damage and repair at the level of the gene in Chinese hamster ovary cells. J. Biol. Chem., 265: 13906–13913, 1990.PubMedGoogle Scholar
  52. 52.
    Matsuo, N., and Ross, P.M. Measurement of interstrand cross-link frequency and distance between interruptions in DNA exposed to 4,5′,8-trimethylpsoralen and near-ultraviolet light. Biochemistry, 26: 2001–2009, 1987.CrossRefPubMedGoogle Scholar
  53. 53.
    Kohn, K.W. Molecular mechanisms of cross-linking by alkylating agents and platinum complexes. In: A.C. Sartorelli, J.S. Lazlo and J.R. Bertino (eds.), Molecular actions and targets for cancer chemotherapeutic agents, pp. 3–16, New York: Academic Press. 1981.Google Scholar
  54. 54.
    Holler, E., Bauer, R., and Bernges, F. Monofunctional DNA-platinum(II) adducts block frequently DNA polymerases. Nucleic. Acids Res., 20: 2307–2312, 1992.CrossRefPubMedGoogle Scholar
  55. 55.
    Naegeli, H. Roadblocks and detours during DNA replication: Mechanisms of mutagenesis in mammalian cells. Bioessays, 16: 557–564, 1994.CrossRefPubMedGoogle Scholar
  56. 56.
    Sweasy, J.B., Witkin, E.M., Sinha, N., and Roegner-Maniscalco, V. RecA protein of Escherichia coli has a third essential role in SOS mutator activity. J. Bacteriol., 172: 3030–3036, 1990.PubMedGoogle Scholar
  57. 57.
    Frank, E.G., Hauser, J., Levine, A.S., and Woodgate, R. Targeting of the UmuD, UmuD’, and MucA’ mutagenesis proteins to DNA by RecA protein. Proc. Natl. Acad. Sci. USA, 90: 8169–8173, 1993.CrossRefPubMedGoogle Scholar
  58. 58.
    Hurwitz, J., Dean, F.B., Kwong, A.D., and Lee, S.-H. The in vitro replication of DNA containing the SV40 origen. J. Biol. Chem., 265: 18043–18046, 1990.PubMedGoogle Scholar
  59. 59.
    O’Day, C.L., Burgers, P.M.J., and Taylor, J.S. PCNA-induced DNA synthesis past cis-syn and trans-syn-I thymine dimers by calf thymus DNA polymerase delta in vitro. Nucleic. Acids Res., 20: 5403–5406, 1992.CrossRefPubMedGoogle Scholar
  60. 60.
    Hughes, E.N., Engelsberg, B.N., and Billings, P.C. Purification of nuclear proteins that bind to cisplatin-damaged DNA — Identity with high mobility group protein-1 and protein-2. J. Biol Chem., 267: 13520–13527, 1992.PubMedGoogle Scholar
  61. 61.
    Donahue, B.A., Augot, M., Bellon, S.F., Treiber, D.K., Tonry, J.H., Lippard, S.J., and Essigmann, J.M. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry, 29: 5872–5880, 1990.CrossRefPubMedGoogle Scholar
  62. 62.
    Brown, S.J., Kellett, P J., and Lippard, S.J. Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science, 261: 603–605, 1993.CrossRefPubMedGoogle Scholar
  63. 63.
    Andrews, P.A. and Jones, J.A. Characterization of binding proteins from ovarian carcinoma and kidney tubule cells that are specific for cisplatin modified DNA. Cancer Commun., 3: 93–102, 1991.PubMedGoogle Scholar
  64. 64.
    Vaisman, A., and Chaney, S.G. Induction of UV-damage recognition protein by cisplatin treatment. Biochemistry, 34: 105–114, 1995.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Stephen G. Chaney
    • 1
  • Edward L. Mamenta
    • 1
  1. 1.Department of Biochemistry and Biophysics, Lineberger Comprehensive, Cancer Center and Curriculum in ToxicologyUniversity of North CarolinaChapel HillUSA

Personalised recommendations